Alk-Abello AS (OCSE:ALK B) is set to release its Q3 2024 earnings on Nov 14, 2024. The consensus estimate for Q3 2024 revenue is $1.31 billion, and the earnings are expected to come in at $0.90 per ...

ALK, a global specialty pharmaceutical company focused on allergy and allergic asthma, announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (ARS ...

ALK-Abelló has acquired rights to Neffy adrenaline nasal spray in Europe and Canada, amongst other countries, from ARS ...

Last month, another incident involved a case of bullying at the same university, with an ALK UPNM cadet officer being brought ...

ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak ...

Alaska Airlines overpaid for Hawaiian Holdings, acquiring a financially troubled airline. Click here to read why ALK stock is ...

Under the latest deal, ARS is in line to receive up to $320 million in regulatory and sales milestones, plus tiered, double-digit royalties in the teens on net sales in places where ALK will market ...

In the past week, Alaska Air Group ALK and SkyWest SKYW reported better-than-expected earnings per share and revenues for the ...

During a Case-Based Roundtable® event, Chul Kim, MD, discussed the ALTA-1 trial and BRIGHTSTAR trials of brigatinib in ALK+ ...

Commercial launch of neffy®(epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by ...

ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY). The agreement grants ALK ...

KUALA LUMPUR, Nov 12 (Bernama) -- There is no need to reshuffle the administration of Military Training Academy (ALK) ...